S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Laser breakthrough could send stock soaring 2,467% (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Laser breakthrough could send stock soaring 2,467% (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Laser breakthrough could send stock soaring 2,467% (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
Laser breakthrough could send stock soaring 2,467% (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Earnings Date, Estimates & Call Transcripts

$7.89
-0.11 (-1.38%)
(As of 06/9/2023 ET)
Compare
Today's Range
$7.72
▼
$8.05
50-Day Range
$5.36
▼
$9.06
52-Week Range
$5.28
▼
$13.44
Volume
3.56 million shs
Average Volume
7.08 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.09
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 3Estimated
Actual EPS
(May. 9)
-$0.50 Beat By $0.34
Consensus EPS
(May. 9)
-$0.84
Last Year's Q2 EPS
(5/5/2022)
-$0.58
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

IOVA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IOVA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Iovance Biotherapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($1.52)($0.49)($0.99)
Q2 20233($1.43)($0.52)($0.82)
Q3 20233($0.57)($0.51)($0.54)
Q4 20233($0.64)($0.54)($0.58)
FY 202313($4.16)($2.06)($2.93)
Q1 20242($0.48)($0.38)($0.43)
Q2 20242($0.44)($0.32)($0.38)
Q3 20242($0.37)($0.35)($0.36)
Q4 20242($0.34)($0.24)($0.29)
FY 20248($1.63)($1.29)($1.46)
Q1 20251($0.30)($0.30)($0.30)

IOVA Earnings Date and Information

Iovance Biotherapeutics last issued its quarterly earnings data on May 9th, 2023. The biotechnology company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.34. Iovance Biotherapeutics has generated ($2.40) earnings per share over the last year (($2.40) diluted earnings per share). Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($2.34) to ($1.54) per share. Iovance Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 3rd, 2023 based off prior year's report dates.

Iovance Biotherapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/3/2023
(Estimated)		        
5/9/2023Q1 2023($0.84)($0.50)+$0.34($0.50)    
2/28/2023Q4 2022($0.64)($0.64)($0.64)    
11/3/2022Q3 2022($0.64)($0.63)+$0.01($0.63)
8/4/2022Q2 2022($0.60)($0.63)($0.03)($0.63)    
5/5/2022Q1 2022($0.64)($0.58)+$0.06($0.58)$12.00 million    
2/24/2022Q4 2021($0.56)($0.63)($0.07)($0.63)    
11/4/20219/30/2021($0.53)($0.55)($0.02)($0.55)    
8/5/20216/30/2021($0.51)($0.53)($0.02)($0.53)    
5/6/20213/31/2021($0.48)($0.51)($0.03)($0.51)  
2/24/202112/31/2020($0.44)($0.47)($0.03)($0.47)  
11/5/20209/30/2020($0.46)($0.40)+$0.06($0.40)  
8/6/20206/30/2020($0.52)($0.47)+$0.05($0.47)  
5/5/20203/31/2020($0.53)($0.55)($0.02)($0.55)  
2/25/2020Q4 2019($0.42)($0.50)($0.08)($0.50)  
11/4/2019Q3 2019($0.39)($0.40)($0.01)($0.40)  
8/1/2019Q2 2019($0.29)($0.38)($0.09)($0.38)
5/7/20193/31/2019($0.29)($0.30)($0.01)($0.30)
2/27/2019Q4 2018($0.27)($0.27)($0.27)
11/6/2018Q3($0.33)($0.36)($0.03)($0.36)
8/6/2018Q2($0.32)($0.34)($0.02)($0.34)
5/10/2018Q1 2018($0.2880)($0.3140)($0.0260)($0.31)
3/12/2018Q4 2017($0.3220)($0.36)($0.0380)($0.36)  
10/31/2017Q3 2017($0.34)($0.35)($0.01)($0.35)
8/1/2017Q2 2017($0.35)($0.37)($0.02)($0.37)
5/1/2017Q1 2017($0.28)($0.33)($0.05)($0.33)  
3/7/2017Q4 2016($0.25)($0.25)($0.25)  
11/4/2016Q316($0.22)($0.32)($0.10)$0.51
8/8/2016Q2 2016($0.19)($0.23)($0.04)($0.23)
5/9/2016Q1 2016($0.16)($0.14)+$0.02($0.14)
3/10/2016Q4($0.20)($0.20)($0.20)
11/5/2015Q3 2015($0.20)($0.16)+$0.04($0.16)
8/10/2015Q2 2015($0.17)($0.14)+$0.03($0.14)
5/11/2015Q1 2015($0.11)($0.14)($0.03)($0.14)












Iovance Biotherapeutics Earnings - Frequently Asked Questions

When is Iovance Biotherapeutics's earnings date?

Iovance Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 3rd, 2023 based off last year's report dates. Learn more on IOVA's earnings history.

Did Iovance Biotherapeutics beat their earnings estimates last quarter?

In the previous quarter, Iovance Biotherapeutics (NASDAQ:IOVA) reported ($0.50) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.84) by $0.34. Learn more on analysts' earnings estimate vs. IOVA's actual earnings.

How can I listen to Iovance Biotherapeutics's earnings conference call?

The conference call for Iovance Biotherapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Iovance Biotherapeutics's conference call transcript?

The conference call transcript for Iovance Biotherapeutics's latest earnings report can be read online. Read Transcript

How much profit does Iovance Biotherapeutics generate each year?

Iovance Biotherapeutics (NASDAQ:IOVA) has a recorded net income of -$395.89 million. IOVA has generated -$2.40 earnings per share over the last four quarters.

What is Iovance Biotherapeutics's EPS forecast for next year?

Iovance Biotherapeutics's earnings are expected to grow from ($2.34) per share to ($1.54) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:IOVA) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -